Podcasts about Genomics

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Sophie sits down with Erika Gray, co-founder of Toolbox Genomics, to break down how your genes affect detoxification, your ability to clear hormones, toxins, histamine, caffeine, and more.They talk about what happens when detox pathways run too fast or too slow, why environment matters just as much as genetics, and how understanding your unique blueprint can make detox and supplementation actually work better.Sophie also shares details about their new collaboration, where you can run your Detoxification Panel through Toolbox Genomics and get a personalized detox plan created just for you.Connect with Toolbox Genomics:toolboxgenomics.comWork with Sophie:shetalkshealth.comDisclaimer: This information is being provided to you for educational and informational purposes only. It is being provided to educate you about how to take care of your body and as a self-help tool for your own use so that you can reach your own health goals. It is not intended to treat or cure any specific illness and is not to replace the guidance provided by your own medical practitioner. If you are under the care of a healthcare professional or currently use prescription medications, you should discuss any dietary changes or potential dietary supplement use with your doctor, and should not discontinue any prescription medications without first consulting your doctor. This information is to be used at your own risk based on your own judgment. If you suspect you have a medical problem, we urge you to take appropriate action by seeking medical attention.

If you like genomics, you'll love our question of the week! It's a brand new week, so we have a brand new question. And if you are looking to buy for that hard-to-buy-for person, we have a couple of unique gift ideas!

When Julia Stalder heard the words ductal carcinoma in situ, she was told she had the “best kind of breast cancer.” Which is like saying you got hit by the nicest bus. Julia's a lawyer turned mediator who now runs DCIS Understood, a new nonprofit born out of her own diagnosis. Instead of panicking and letting the system chew her up, she asked questions the industry would rather avoid. Why do women lose breasts for conditions that may never become invasive? Why is prostate cancer allowed patience while breast cancer gets the knife? We talked about doctors' fear of uncertainty, the epidemic of overtreatment, and what happens when you build a movement while still in the waiting room. Funny, fierce, unfiltered—this one sticks.RELATED LINKS• DCIS Understood• Stalder Mediation• Julia's story in CURE Today• PreludeDx DCISionRT feature• Julia on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon.

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/asian-review

Jian Lian is an expert on China's political economy, industrial development, and technological development. He graduated from Peking University with a bachelor's and master's degree in economics. Starting out as an industry analyst at a Chinese investment bank, he participated in the "Made in China 2025" initiative as a Chinese venture capitalist, working for a state-owned fund. He is the author of "The Truth About Capital" 资本的真相 (2016), which contains major predictions about technology, economy, and society in China, most of which have since come true.Jian and Steve discuss the origins of the industrial party movement (discussed in an earlier episode with Kyle Chan), which culminated in the "industrial maximalism" view of development adopted by the PRC government. They also discuss the development of supply chains in China, and the role that US sanctions had in accelerating the Chinese semiconductor industry.Kyle Chan episode:https://www.manifold1.com/episodes/kyle-chan-on-the-future-of-us-china-competition-94Chinese industrial maximalism: https://www.high-capacity.com/p/chinese-industrial-maximalism(00:00) - Introduction (00:49) - Jian Gaokao score was 23rd in all of Fujian = Econ at Beida, not Genomics! (05:21) - China's Industrial Policy and Innovation (24:19) - Domestic supply chain strategy; How Huawei became a national champion due to US sanctions (34:13) - Venture Capital in China (36:13) - Hard Tech Investments (37:40) - Regulations of Tech Giants (44:28) - Future of China Technological Development –Steve Hsu is Professor of Theoretical Physics and of Computational Mathematics, Science, and Engineering at Michigan State University. Previously, he was Senior Vice President for Research and Innovation at MSU and Director of the Institute of Theoretical Science at the University of Oregon. Hsu is a startup founder (SuperFocus.ai, SafeWeb, Genomic Prediction, Othram) and advisor to venture capital and other investment firms. He was educated at Caltech and Berkeley, was a Harvard Junior Fellow, and has held faculty positions at Yale, the University of Oregon, and MSU.Please send any questions or suggestions to manifold1podcast@gmail.com or Steve on X @hsu_steve.

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices

In 2016, Ludovic Orlando, a genetics researcher, embarked on the Pegasus Project, an ambitious endeavor to use genetics to discover the origin of the modern horse. There were plenty of theories as to who domesticated horses first–but Ludovic's team came up with their answer: They emerged on the western Eurasian steppe around 4200 years ago. But that revelation was only the beginning of Ludovic's work, as he dug into the genetic origins of different kinds of horses, like the Arabian horse, as well as charted how the horse's genetic diversity changed over time. His research is collected in his new book Horses: A 4,000-Year Genetic Journey Across the World (Princeton UP, 2025) Ludovic Orlando is a CNRS Silver Medal–winning research director and founding director of the Centre for Anthropobiology and Genomics of Toulouse at the University of Toulouse in France. His work has appeared in leading publications such as Nature, Science, and Cell. He is a recipient of the American Association for the Advancement of Science's Newcomb Cleveland Prize. You can find more reviews, excerpts, interviews, and essays at The Asian Review of Books, including its review of Horses. Follow on Twitter at @BookReviewsAsia. Nicholas Gordon is an editor for a global magazine, and a reviewer for the Asian Review of Books. He can be found on Twitter at@nickrigordon. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/animal-studies

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of WoodChat, we take a deeper look at how genetics is reshaping Australia's forestry sector. Building on our FWPA article 'The power of genetics: growing stronger, more productive plantations', we explore the science and strategy behind improving forest stock, boosting yield and strengthening the resilience of plantations. Our guests unpack the major gains achieved in plantation forestry so far, how tree breeding can help future-proof forests in a changing climate, and what current funding levels mean for accelerating genetic improvement at scale. We also dig into what's working, what isn't, and the opportunities ahead for the industry. Featuring: • Dr Tony McRae, General Manager, Tree Breeding Australia • Dominic Kain, Tree Breeder and Geneticist, HQPlantations • Josquin Tibbits, Senior Research Scientist, Department of Environment and Primary Industries This episode is ideal for anyone interested in forestry innovation, timber research, plantation genetics and the work supported by Forest and Wood Products Australia. Theme tune: 'Macaroon 5' by Audionautix is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/...) Artist: http://audionautix.com/

Many nurses lack confidence in applying genomics in practice, highlighting the need for improved genomics nursing education. The International Society for Nurses in Genetics convened a steering committee to develop a competency framework defining the role of Genomics Nurse Educators. This podcast with Dr. Deborah O. Himes presents strategies nurse educators can use to teach genomics application through a nursing program. Read the full article – it is OPEN Access (and share with colleagues).

In this explainer episode, we've asked Amanda Pichini, clinical director at Genomics England and genetic counsellor, to explain what a genetic counsellor is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is a genetic counsellor? I'm Florence Cornish, and today I'm joined with Amanda Pichini, a registered genetic counsellor and clinical director for Genomics England, to find out more.   So, before we dive in, lots of our listeners have probably already heard the term genetic counsellor before, or some people might have even come across them in their healthcare journeys. But for those who aren't familiar, could you explain what we mean by a genetic counsellor?  Amanda: Genetic counsellors are healthcare professionals who have training in clinical genomic medicine and counselling skills. So they help people understand complex information, make informed decisions, and adapt to the impact of genomics on their health and their family. They're expert communicators, patient advocates, and navigators of the ethical issues that genomics and genomic testing could bring.  Florence: Could you maybe give me an example of when somebody might see a genetic counsellor?   Amanda: Yes, and what's fascinating about genetic counselling is that it's relevant to a huge range of conditions, scenarios, or points in a person's life.  Someone's journey might start by going to their GP with a question about their health. Let's say they're concerned about having a strong family history of cancer or heart disease, or perhaps a genetic cause is already known because it's been found in a family member and they want to know if they've inherited that genetic change as well.   Or someone might already be being seen in a specialist service, perhaps their child has been diagnosed with a rare condition. A genetic counsellor can help that family explore the wide-ranging impacts of a diagnosis on theirs and their child's life, how it affects their wider family, what it might mean for future children. You might also see a genetic counsellor in private health centres or fertility clinics, or if you're involved in a research study too.   Florence: And so, could you explain a bit more about the types of things a genetic counsellor does? What does your day-to-day look like, for example?   Amanda: Most genetic counsellors in the UK work in the NHS as part of a team alongside doctors, lab scientists, nurses, midwives, or other healthcare professionals. Their daily tasks include things like analysing a family history, assessing the chance of a person inheriting or passing on a condition, facilitating genetic tests, communicating results, supporting family communication, and managing the psychological, the emotional, the social, and the ethical impacts of genetic risk or results.   My day-to-day is different though. I and many other genetic counsellors have taken their skills to other roles that aren't necessarily in a clinic or seeing individual patients. It might involve educating other healthcare professionals or trainees, running their own research, developing policies, working in a lab, or a health tech company, or in the charity sector.   For me, as Clinical Director at Genomics England, I bring my clinical expertise and experience working in the NHS to the services and programmes that we run, and that helps to make sure that we design, implement, and evaluate what we do safely, and with the needs of patients, the public, and healthcare professionals at the heart of what we do.    My day-to-day involves working with colleagues in tech, design, operations, ethics, communications, and engagement, as well as clinical and scientific experts, to develop and run services like the Generation Study, which is sequencing the genomes of 100,000 newborn babies to see if we can better diagnose and treat children with rare conditions.  Florence: So, I would imagine that one of the biggest challenges of being a genetic counsellor is helping patients to kind of make sense of the complicated test results or information, but without overwhelming them. So how do you balance kind of giving people the scientific facts and all the information they need, but while still supporting them emotionally?   Amanda: This is really at the core of what genetic counsellors can do best, I think. Getting a diagnosis of a rare condition, or finding out about a risk that has a genetic component, can come with a huge range of emotions, whether that's worry, fear, or hope and relief.  It can bring a lot of questions, too. What will this mean for my future or my family's future? What do you know about this condition? What sort of symptoms could I have? What treatments or screening might be available to me? So genetic counsellors are able to navigate all of these different questions and reactions by giving an opportunity for patients and families to discuss their opinions, their experiences, and really trying to get at the core of understanding their values, their culture, their expectations, their concerns, so that they can help that individual make an informed decision that's best for them, help them access the right care and support, adjust or find healthy coping strategies, or maybe even change their lifestyle or health behaviours. So it's really finding that balance between the science, the clinical aspects, the information, and the support.  Florence: So obviously working in this space, I get to read about lots of incredible research all the time, and it feels like genetics and genomics seems to be changing and advancing day by day. So, I'd be interested to know what this means for you and for other genetic counsellors, what's coming next?   Amanda: Yeah, so as we continue to see advances in genetics and genomics, there's, I think, a really increasing need for genetic counselling expertise to help shape how these technologies are used and with giving the right consideration for the challenges around what this means for families and for wider society.  Genomics is also still growing the evidence base it needs to provide a consistent and equitable service. We're seeing digital tools being increasingly available to give people information in innovative ways, seeing huge advancements in targeted treatments and gene therapies, that are changing fundamentally the experiences of people living with rare conditions and cancers. And we're using genomics more and more to predict future health risks and how people might respond to certain medications. So, there's a huge amount that we're seeing sort of coming for the future.   What's interesting is the 10-Year Health Plan that the government has set out for the NHS provides, I think, huge opportunities for genomics. For example, we'll see healthcare brought closer to local communities, genomics being used as part of population health, reaching people closer to where they are and hopefully providing greater access.   But I think the key thing in all of this is knowing that genomics is really just a technology. It requires people with the right skill sets to use it safely and to be able to benefit everyone, and genetic counsellors are a huge part of that.   Florence: And finally, in case anyone listening has been inspired by this conversation and wants to build a career like yours, what advice would you have to offer somebody hoping to become a genetic counsellor in the future?   Amanda: To train as a genetic counsellor in the UK, you usually need an undergrad degree in biological sciences, psychology, or being a nurse or midwife. The background can be varied, but usually driven by a common thread, a desire to sort of improve healthcare experiences for patients and make genomic healthcare widely accessible and safely used for everyone.  You can apply for the 3-year NHS scientist training programme, or there's also master's degrees offered through Cardiff University, for example. In general, I'd encourage people to check out the website for the Association of Genetic Nurses and Counsellors, and reach out to genetic counsellors to ask about their career and their journey as much as possible, as well as seeking opportunities to really understand the experiences of people living with rare genetic conditions, because that will help you understand the ways in which genetic counselling can have an impact.  Florence: We'll finish there. Thank you so much, Amanda, for all of those insights and for explaining what it means to be a genetic counsellor. If any listeners want to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk or wherever you get your podcasts.  Thank you for listening. 

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

DAVID MELTZER: PEOPLING OF THE AMERICAS Peopling of the Americas as Inferred from Ancient Genomics 1. Professor David Meltzer, an archaeologist, discusses how genomics provides a breakthrough over earlier methods like mitochondrial DNA by using the entire genome to reveal the complex tapestry of ancestry, showing mixing and cross-breeding among populations. Ancestral Native Americans arose from the admixture of Ancient North Siberians and an East Asian population around 26,000 to 24,000 years ago. During the last glacial maximum (23,000–19,000 years ago), lower sea levels exposed the land bridge connecting Siberia and Alaska, and these distinctive ancestral groups became isolated due to harsh glacial cold, positioning themselves to move further south.

Patterns of Isolation and Continuity in the Americas 4. Professor Meltzer notes that rapid dispersal and substantial population increase characterized the first peoples in the Americas, leading to early isolation and the emergence of subgroups through both geographic constraints like the Andes Mountains and social isolation due to increasing territoriality. Some areas show strong genomic continuity over millennia while others show discontinuity, with populations being displaced or replaced, and later influxes occurred around 6,000 years ago as maritime groups began crossing the Bering Sea, causing further admixture. Genomics is also used to study indigenous health history, including the incidence of diseases like tuberculosis, to help present-day descendants and confirm the devastating impact of infectious diseases introduced by Europeans.

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On today's show, Steve Roest, CEO of PocDoc speaks to Dr Natalie Banner is Chief Ethics and Engagement Officer at Genomics England, an organisation owned by the UK Government to provide the evidence and digital systems to drive advances in genomic research and medicine, and to support the implementation of genomics in healthcare.Genomics is being hailed as one of the big developments that will usher in an age of health, wealth and prosperity, but do you really know what it means? And what the ethical issues are around mapping our entire genetic structures?Natalie is responsible for helping Genomics England navigate the complex ethical challenges that arise at the intersection of genomic technology and care, ensuring that the organisation is a trustworthy steward of participants' data. This includes oversight for research regulatory compliance, extensive public and research participant engagement work, improving transparency and embedding meaningful approaches to equity across its programmes.Natalie has over a decade of experience in the ethics, policy and governance of emerging data-driven health technologies. She previously led the ‘Understanding Patient Data' initiative based at the Wellcome Trust, as well as the research sector Parliamentary advocacy on GDPR as it was being taken up into domestic law. She has a PhD in Philosophy and previously worked on conceptual issues relating to mental capacity and decision-making in clinical contexts.

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

In this episode of Ageless Future, Regan Archibald sits down with Dr. Aaron Hartman, a leading integrative and functional medicine physician from Richmond, Virginia, to explore how personal struggle reshaped his medical philosophy. Dr. Hartman shares the remarkable story of his adopted daughter, Anna, who was born with severe neurological challenges after prenatal drug exposure and was given little hope by conventional medicine. Refusing invasive interventions, Dr. Hartman and his wife instead pioneered a personalized, root-cause approach—combining nutrition, genomic testing, hyperbaric therapy, peptides, and stem cells—to help Anna achieve milestones doctors said were impossible. Their journey reveals both the shortcomings of standard medical systems and the transformative power of curiosity, persistence, and faith. The conversation expands to the healing of mothers, trauma recovery, and how functional medicine empowers both patients and practitioners to think, innovate, and restore true health. LIKE/FOLLOW/SUBSCRIBE DR. HARTMAN:Website: https://uncurablebook.com/YouTube: https://www.youtube.com/c/AaronHartmanMDInstagram: https://www.instagram.com/rvaintegrative/Facebook: https://www.facebook.com/RVAintegrativeLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube: https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureInstagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Host Matt Burgess talks with Dr Jodie Ingles, a leading cardiac genetic counsellor and researcher, about inherited heart conditions, supporting families after sudden cardiac events, and translating genomic discoveries into clinical care. The episode covers variant classification, health equity, the evolving role of genetic counsellors, and the importance of mentorship and practical changes needed to bring genomic testing into everyday practice.

It's The Ranch It Up Radio Show! Join Jeff Tigger Erhardt, Rebecca Wanner AKA BEC and their crew as they hear the latest reactions to potential imports of Argentine Beef.  Plus, part 2 of genomically testing the cow herd and when it comes to nutrition, don't forget about the bulls.  Plus, market reports, upcoming sales and lots more on this all-new episode of The Ranch It Up Radio Show.  Be sure to subscribe on your favorite podcasting app or on the Ranch It Up Radio Show YouTube Channel. Season 5, EPISODE 260 Cattle & Producer Groups React To Potential Imports of Argentine Beef   Last Sunday President Donald Trump said the United States could purchase Argentinian beef in an attempt to bring down prices for American consumers.  This sparked immediate reaction from our cattle associations and organizations. Reference: https://apnews.com/article/beef-argentina-us-consumers-prices-f7fadbe1b3fef4646f9c3623f901209a National Cattlemen's Beef Association (NCBA) Reaction To Argentine Beef NCBA's family farmers and ranchers have numerous concerns with importing more Argentinian beef to lower prices for consumers. This plan only creates chaos at a critical time of the year for American cattle producers, while doing nothing to lower grocery store prices," said NCBA CEO Colin Woodall. "Additionally, Argentina has a deeply unbalanced trade relationship with the U.S. In the past five years Argentina has sold more than $801 million of beef into the U.S. market. By comparison, the U.S. has sold just over $7 million worth of American beef to Argentina. Argentina also has a history of foot-and-mouth disease, which if brought to the United States, could decimate our domestic livestock production. REFERENCE: https://www.nationalbeefwire.com/ncba-argentinian-beef-import-plan-harms-u-s-cattle-producers United States Cattlemen's Association (USCA) Reaction To Argentine Beef The current price of beef on grocery store shelves reflects the true, inflation-adjusted cost of raising cattle in America today.  Already this year, the U.S. has imported more than 1.26 million metric tons of beef, primarily from Australia, Canada, Brazil, Mexico, and New Zealand. Increasing imports under current rules ultimately benefits foreign suppliers and multinational packers, while putting U.S. ranchers on the losing end and depriving American consumers of honest transparency at the meat counter. REFERENCE: https://www.nationalbeefwire.com/usca-comments-on-president-trump-s-remarks-regarding-beef-prices-and-proposed-imports-from-argentina R-Calf USA Reaction To Argentine Beef Global packers are importing beef from about 20 different countries, including Argentina, and because we do not have a mandatory country-of-origin labeling law for beef, the global packers do not need to reduce the price of imported product compared to domestic product. This negates any theoretical benefit of using more imports to drive down domestic beef prices. We urge the president to manage imports, restore mandatory country-of-origin labeling for beef, and put an end to the monopolistic control that packers and retailers have over our beef supply chain. Doing so will incentivize America's ranchers to rebuild and expand the U.S. herd to meet our national security needs and ensure that consumer beef prices are determined by competitive market forces. REFERENCE: https://www.nationalbeefwire.com/statement-on-plan-to-increase-argentine-beef-imports Fall Bull Nutrition From Westway Feed Products Nutritional balance is a cornerstone of herd health and productivity. According to Dr. Kelly Sanders of Westway Feed Products, deficiencies often go unnoticed until performance suffers. Signs Of Nutritional Deficiencies In Cattle Poor Body Condition: Thin cows, visible ribs, or weak muscling. Reduced Fertility: Open cows, delayed cycling, or poor conception rates. Coat and Hoof Issues: Rough hair coats, brittle hooves, or slow shedding. Growth Challenges in Calves: Reduced weight gains or uneven growth patterns. How To Correct Deficiencies Forage Testing: Identify nutrient gaps in hay and pasture. Targeted Supplementation: Provide liquid or block supplements to balance protein, energy, and minerals. Management Adjustments: Ensure adequate feed availability during high-demand stages such as lactation and breeding. Dr. Sanders emphasizes that proactive nutrition not only boosts herd performance but also maximizes returns on investment in genetics. Ideal Beef Genetics:  The Power Of Genomics In The Cow Herd   The Science of Selection With GEPDs from the Ideal Beef Evaluation, selecting replacement females becomes a science, not an art. Using 15 different traits, and custom indexes that combine and simplify them, phenotype and pedigree are no longer the only tools at your disposal to guide the future of your herd. Prove Your Pedigree Genotyping your herd with IBG allows parentage verification so you know where your herd comes from. All Herd and AI sires available from Jorgensen Land and Cattle are genotyped and available for sire match, and all of your genotyped females will match with their progeny. The Power of Genomic Analytics Visualize Your Results Enrolling your cattle in the IBG service gives you access to AgBoost, a revolutionary technology that turns confusing genomic results into easy to understand visualizations. This allows you to cut through the clutter and focus on your herd's future. Matings Made Easy Females enrolled in IBG are eligible for breeding suggestions powered by industry leading analytics. You pick your desired breeding outcomes, and your females will be analyzed next to Jorgensen Land and Cattles 5000+ Herd and AI sire battery, ensuring the bulls you turn out are the best for your herd's future. Enroll Cow Herd In Genomic Testing With Jorgensen Land & Cattle Gather Tissue Samples:  TSU's and Collectors are available at no charge upon request Send Samples & Data:  We handle ordering test, shipping samples & delivery of results Review Your Results: Evaluation results are loaded into your AgBoost Profile, so you are sure to have the most up to date & accurate GEPD's at your disposal Select Your Females: Use your herd's genomics to pick the best females to keep Select Your Bulls: We work with you to determine the breeding outcomes best for your herd and pick bulls that best meet those needs Featured Experts in the Cattle Industry Dr. Kelly Sanders – Westway Feed Products https://westwayfeed.com/ Follow on Facebook: @WestwayFeed Larry Gran – Jorgensen Land & Cattle https://jorgensenfarms.com/ Follow on Facebook: @JorLandCat Mark Vanzee – Livestock, Equine, & Auction Time Expert https://www.auctiontime.com/ https://www.livestockmarket.com/ https://www.equinemarket.com/ Follow on Facebook: @LivestockMkt | @EquineMkt | @AuctionTime Kirk Donsbach – Financial Analyst at StoneX https://www.stonex.com/ Follow on Facebook: @StoneXGroupInc Shaye Wanner – Host of Casual Cattle Conversation https://www.casualcattleconversations.com/ Follow on Facebook: @cattleconvos Contact Us with Questions or Concerns Have questions or feedback? Feel free to reach out via: Call/Text: 707-RANCH20 or 707-726-2420 Email: RanchItUpShow@gmail.com Follow us: Facebook/Instagram: @RanchItUpShow YouTube: Subscribe to Ranch It Up Channel: https://www.youtube.com/c/RanchItUp Catch all episodes of the Ranch It Up Podcast available on all major podcasting platforms. Discover the Heart of Rural America with Tigger & BEC Ranching, farming, and the Western lifestyle are at the heart of everything we do. Tigger & BEC bring you exclusive insights from the world of working ranches, cattle farming, and sustainable beef production. Learn more about Jeff 'Tigger' Erhardt & Rebecca Wanner (BEC) and their mission to promote the Western way of life at Tigger and BEC. https://tiggerandbec.com/ Industry References, Partners and Resources For additional information on industry trends, products, and services, check out these trusted resources: Allied Genetic Resources: https://alliedgeneticresources.com/ American Gelbvieh Association: https://gelbvieh.org/ Axiota Animal Health: https://axiota.com/multimin-campaign-landing-page/ Imogene Ingredients: https://www.imogeneingredients.com/ Jorgensen Land & Cattle: https://jorgensenfarms.com/#/?ranchchannel=view Medora Boot: https://medoraboot.com/ RFD-TV: https://www.rfdtv.com/ Rural Radio Network: https://www.ruralradio147.com/ Superior Livestock Auctions: https://superiorlivestock.com/ Transova Genetics: https://transova.com/ Westway Feed Products: https://westwayfeed.com/ Wrangler: https://www.wrangler.com/ Wulf Cattle: https://www.wulfcattle.com/

In this episode, host Lindsey Elizabeth Cortes, a sports dietitian and entrepreneur, delves into the world of female athlete nutrition with guest Nick Padula, a private practice sports dietitian and professor at the University of Southern California. They discuss the importance of personalized nutrition, the impact of dietary choices on performance, and the power of comprehensive testing, including continuous glucose monitors (CGMs), genomics, and microbiome analysis.   Nick shares his experiences working with various athletes, from boxers to endurance runners, and underscores how detailed nutrition data can significantly enhance training and recovery. Lindsey and Nick also explore practical approaches to fueling for both everyday athletes and elite sports performers, emphasizing the difference between generalized guidelines and individualized nutritional insights.   Episode Highlights: 01:24 Meet Nick Padula: Sports Dietician Extraordinaire 02:50 The Intersection of Clinical and Sports Nutrition 04:14 The Science and Ethics of Weight Cutting 09:52 Customizing Nutrition Through Testing 17:06 Understanding Genomic and Microbiome Testing 26:26 Addressing RED-S and Support Options 29:13 Understanding Gluten Intolerance 32:28 The Role of Continuous Glucose Monitors (CGMs) 35:37 Practical Applications of CGMs 42:05 The Importance of Recovery Nutrition 45:30 Exploring Nutrition Packages and Testing 47:07 The Impact of Environmental Toxins 53:31 Fun Questions and Final Thoughts Nick Padula has been a practicing Dietitian since 2015 as a clinical dietitian, a foodservice director. In addition to You Trition, LBC Nutrition, a dietetic consultant company, is a lecturer and coordinator with the University of Southern California Master’s in Nutrition program and Sports Dietitian for Cypress Junior College Athletics. ⁠   Nick studied nutrition and dietetics at Long Beach State University and received a Bachelor's degree in 2012 and Master's degree in Nutrition and Dietetics with a concentration in Sports Nutrition from Texas Tech University. ⁠In his practice he has worked with triathletes, professional boxers, endurance runners, professional soccer players, high school athletes, and the USC football and basketball teams. Nick is an avid runner, weightlifter, and golfer.   Connect with Nick: www.youtritionscience.com IG:@Youtrition_science Email: nick@youtritionscience.com   Resources and Links: For more information about the show, head to work with Lindsey on improving your nutrition, head to: http://www.lindseycortes.com/ Join REDS Recovery Membership: http://www.lindseycortes.com/reds WaveBye Supplements – Menstrual cycle support code LindseyCortes for 15% off: http://wavebye.co Previnex Supplements – Joint Health Plus, Muscle Health Plus, plant-based protein, probiotics, and more; code riseup for 15% off: previnex.com Female Athlete Nutrition Podcast Archive & Search Tool – Search by sport, condition, or topic: lindseycortes.com/podcast Female Athlete Nutrition Community – YouTube, Instagram @‌femaleathletenutrition, and private Facebook group

Synopsis: Host Rahul Chaturvedi sits down with Geoffrey Duyk, Chief Executive Officer of Grove Biopharma, for a wide-ranging conversation on navigating today's biotech macro headwinds and building companies that can translate breakthrough science into real patient impact. Dr. Duyk traces his journey from Harvard/Millennium/Exelixis operator to TPG investor and back to company creation, explaining how board dynamics, capital cycles, and policy shifts shape execution. They dig into why this cycle feels uniquely tough—patent cliffs, reimbursement uncertainty, NIH pressures—and who funds innovation in the meantime. Duyk outlines root causes of R&D inefficiency (misaligned capital vs. 20-year timelines, shaky preclinical predictability, costly trials, underused real-world data) and makes the case for rebuilding public trust and STEM education. Then, a deep dive on Grove Biopharma: precision polymer science that creates antibody-like, fully synthetic, cell-permeable protein mimetics to tackle historically “intractable” intracellular protein–protein interactions. Duyk shares design principles, why modular/orthogonal chemistry matters, predictable pharmacology, and lessons from fundraising and board management—plus why he's helping grow a Chicago-centered biotech ecosystem. Biography: Geoffrey M. Duyk, M.D., Ph.D. is the Chief Executive Officer of Grove Biopharma. Dr. Duyk has spent 30 years in the biotechnology industry as an entrepreneur, executive, and investor. Most recently, he was the Managing Partner at Circularis Partners, an investment firm he co-founded, focused on advancing the circular economy and promoting sustainability. Prior to that, Dr. Duyk was Managing Director and Partner at TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology. Before joining TPG, Dr. Duyk served as a board member and President of R&D at Exelixis and was one of the founding scientific staff members at Millennium Pharmaceuticals, where he served as Vice President of Genomics. Earlier in his career, Dr. Duyk was an Assistant Professor in the Department of Genetics at Harvard Medical School (HMS) and an Assistant Investigator at the Howard Hughes Medical Institute (HHMI). While at HMS, he served as a co–principal investigator in the Cooperative Human Linkage Center, which was funded by the National Institutes of Health (NIH). Dr. Duyk is a trustee of Case Western Reserve University, where he serves on the executive committee. He previously served on the Board of Trustees of Wesleyan University and the Board of Directors of the Moffitt Cancer Center. He currently serves on the IR&E (Institutional Research and Evaluation) Committee at Moffitt, a key component of its External Advisory Committee (EAC). He was also a member of the Board of Directors of the American Society of Human Genetics (ASHG), and served as its treasurer. He is a member of the Life Sciences Advisory Board at Innovatus Capital Partners and the Scientific Advisory Board (SAB) for Lawrence Berkeley National Laboratory (DOE). Dr. Duyk previously served on the board of the Jackson Laboratory and on numerous NIH advisory committees. He is currently a Senior Advisor at Qiming Venture Partners (USA) and serves on the boards of Enno DC, Oobli, and Melanyze Dr. Duyk earned both his M.D. and Ph.D. from Case Western Reserve University and completed his medical and fellowship training at the University of California, San Francisco (UCSF). While at UCSF, he was a Lucille P. Markey Fellow and an HHMI postdoctoral fellow. He is a fellow of the American Association for the Advancement of Science.

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if the next major leap in aquaculture doesn't come from the ocean but from the genome? In this week's episode, we trace the story of genomic sequencing: from Darwin's first evolutionary trees to the breakthroughs that now let scientists map entire fish genomes in a single day. You'll learn how falling sequencing costs are opening the door to disease tracing, genetic selection, and smarter breeding programs that could redefine sustainability across aquaculture. For more aquaculture insights head to our Fish n' Bits blog.

Associate Professor Jodie Ingles leads Australia’s National Registry for Genetic Heart Disease, bringing together patients and families to improve diagnosis, treatment and understanding of inherited heart conditions through cutting-edge genomic research. Prof. Ingles and her team at the Garvan Institute are researching the genetic causes of inherited heart diseases, such as cardiomyopathies and arrhythmias, which can lead to sudden cardiac death. Their work focuses on identifying the underlying genetic mutations that put individuals and families at risk, using advanced genomic sequencing and data from the National Registry for Genetic Heart Disease. By combining genetic insights with clinical information, they aim to improve diagnosis, guide personalised treatment, and inform family screening. The team also studies how families experience and respond to genetic testing, helping to shape better care and counselling for affected Australians.See omnystudio.com/listener for privacy information.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this explainer episode, we've asked Dr Emily Perry, research engagement manager at Genomics England, to explain what the Genomics England Research Environment is. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. You can listen to the previous episodes mentioned in this podcast How has a groundbreaking genomic discovery impacted thousands worldwide? What is the National Genomic Research Library If you've got any questions, or have any other topics you'd like us to explain, let us know on podcast@genomicsengland.co.uk. You can download the transcript or read it below. Florence: What is the Genomics England Research Environment? My name is Florence Cornish and I'm here with Emily Perry, Research Engagement Manager at Genomics England, to find out more. So Emily, before we dive into the Research Environment, let's set some context. Could you explain what Genomics England is aiming to do as an organisation? Emily: So, Genomics England provides genome sequencing in a healthcare setting for the National Health Service in England. As we sequence genomes for healthcare, the benefit is that we can also put that genomic and clinical data out for research in a controlled manner, and then that can also feed back into healthcare as well. So, it's really, this kind of cyclical process that Genomics England is responsible for. Florence: And so, what do we mean when we say Research Environment? Emily: So, the Research Environment is how our researchers can get access to that clinical and genomic data that we get through healthcare. So, it's a controlled environment, it's completely locked down, so it's kind of like a computer inside a computer. And in there, the researchers can access all of the data that we have and also a lot of tools for working with it in order to do their research. We refer to the data as the National Genomics Research Library, or the NGRL. The NGRL data is provided inside the Research Environment Florence:  So you mentioned the National Genomic Research Library. If any listeners want to learn more about this, you can check out our previous Genomics 101 podcast: What is the National Genomic Research Library? And so Emily, could you talk about what kind of data is stored in this library? Emily: So the library is made up of both genomic data and clinical data, which the researchers use alongside each other. The genomic data includes what we call alignments, which is where we match the reads from sequencing onto a reference sequence, and variants, which is where we identify where those alignments differ from the reference sequence, and this is what we are looking for in genomic research. The clinical data includes the data that was taken from our participants at recruitment, so details of the rare disease, the cancer, that they have, but also medical history data. So, we work with the NHS and we're able to get full medical history for our participants as well. This is all fully anonymised, so there's no names, there's no dates of birth, there's no NHS numbers. It's just these identifiers which are used only inside the Research Environment and have no link to the outside world. Florence: And so how is this clinical and genomic data secured? Emily: So, as I said there's no names, there's no NHS numbers, there's no dates of birth.  And we have very strict criteria for how people can use the data. So researchers, in order to get access to the Research Environment, they have to be a member of a registered institution, they have to submit a project proposal for what it is that they want to study with the data. There's also restrictions on how they can get the data out, so they do all their research inside, there's no way that they can do things like copy and paste stuff out or move files. The only way that they can get data out of the Research Environment is going through a process called Airlock, which is where they submit the files that they want to export to our committee, who then analyse it, check that it's in accordance with our rules and it protects our participants' safety and that only then would they allow them to export it. Florence: Who has access to the Research Environment? Emily: We have researchers working with the Research Environment all over the world. There's 2 kind of major groups. One of them is academia, so this will be researchers working in universities and academic institutions. The other side of it would is industry - so this will be biotech, startups, pharma companies, things like that. Florence: And finally, can you tell us about some of the discoveries that have been made using this data? Emily: There's lots of really cool things that have come out of the Research Environment.  A recent story that came out of the Research Environment was the ReNU syndrome, it was initially just one family that they identified this in, and they were able to extend this discovery across and identify huge numbers of individuals who had this same disorder because they had their genomes within the Research Environment. Florence: You can hear more about this research in our previous Behind the Genes podcast: How has a groundbreaking genomic discovery impacted thousands worldwide? So, we'll wrap up there. Thank you so much, Emily, for sharing more about what we mean by the Genomics England Research Environment. If you'd like to hear more explain episodes like this, you can find them on our website, at www.genomicsengland.co.uk or wherever you get your podcasts. Thank you for listening.  

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of Disruption/Interruption, host KJ sits down with Jim Foote, CEO and founder of First Ascent Biomedical. Jim shares his personal journey from technology executive to cancer care innovator, after his son’s diagnosis changed his life. Discover how he’s disrupting the status quo in oncology with AI-driven, personalized medicine that’s giving new hope to patients and families. Key Takeaways: The Problem with Standard Cancer Care [3:53]The standard of care treats patients as if they are the same, but everyone is unique. This approach works two-thirds of the time, but leaves one-third of patients with few options. Functional Precision Medicine [13:04]Jim’s company tests up to 152 FDA-approved drugs on a patient’s biopsy to find the most effective treatment, providing doctors with data-driven options tailored to each individual. AI and Technology are Transforming Oncology [28:05]Advances in AI, robotics, and cloud computing have converged, making personalized cancer treatment faster, more affordable, and more effective than ever before. Impact and Future Vision [26:51]Jim’s goal is for every cancer patient to receive individualized treatment from the moment of diagnosis, improving outcomes and reducing unnecessary side effects. Quote of the Show (14:40):“I literally have gone from trying and hoping to testing and choosing.” — Jim Foote Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Jim Foote: LinkedIn: http://www.linkedin.com/in/jim-foote Company Website: https://firstascentbiomedical.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Addiction doesn't announce itself- it emerges silently, often after a routine medical procedure. Our next guest, James Piacentino, is changing this reality as CEO and Co-Founder of Thrive Genetics. With over 20 years in healthcare technology and two successful startup exits under his belt, James brings both personal experience and professional expertise to this mission. After losing his father to opioid addiction following a routine surgery, James dedicated his career to ensuring others wouldn't face the same tragedy. By combining cutting-edge genomics with behavioral psychology, Thrive Genetics helps physicians understand a patient's addiction risk before prescribing pain medication. Join us to discover how James and his team are pioneering personalized addiction risk management, transforming how healthcare systems approach prevention, and working to spare millions of families from generational trauma. Let's go!Episode Highlights:Curiosity as the foundation for innovation: James emphasizes that deep curiosity about solving meaningful problems is the key driver that gets him out of bed every morning and the most important quality he looks for in team members.Personal tragedy sparking a mission: After losing his father to opioid addiction following a 1982 car accident and back surgery, James dedicated his career to preventing others from experiencing the same generational trauma.Staggering gap in care: Up to 25% of patients undergoing high-pain procedures become addicted to prescribed opioids, yet no proactive addiction risk assessment exists before prescribing pain medication.Science-backed solution: Thrive Genetics combines 10 years of research and over $50M in NIH grants to create addiction risk scores based on both genetic predisposition (50%) and behavioral factors (50%).Thinking beyond the individual: James' North Star is reaching billions of people by preventing not just individual addiction cases, but stopping generational family trauma before it starts.About our Guest: Thrive Genetics is led by Co-Founder and CEO, James J. Piacentino, MBA, a healthcare technology entrepreneur with over 20 years in tech and life sciences. A graduate of Northwestern University's Kellogg School of Management, James has built and sold two prior startups, published in the Harvard Business Review, and held senior leadership roles at SAP. He is mentored by Harry Kraemer, former CEO of Baxter International and Kellogg Professor of Management.Links Supporting This Episode: Thrive Genetics Website: CLICK HEREJame Piacentino LinkedIn page: CLICK HEREThrive Genetics LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter:

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Deanna Saylor and Dr. Senjuti Saha discuss colonialism in global health and the importance of pathogen genomics.  Show reference:  https://www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00091-8/fulltext

Dr. Deanna Saylor talks with Dr. Senjuti Saha about colonialism in global health and the importance of pathogen genomics.  Read the related article in The Lancet.  Disclosures can be found at Neurology.org. 

In this episode, we talk with two authors who have papers featured in the special issue of the Journal of Genetic Counseling on Research Methods in Genetic Counseling. In the first segment we explore implementation science and its utilization in bridging the gap between research and clinical practice. In our second segment, we talk to an author about retrospective chart reviews and the benefits and drawbacks of this methodology.   Segment 1: A guide to utilizing implementation science for genetic counseling   Alanna Kulchak Rahm is a certified genetic counselor and implementation scientist with a PhD in Health and Behavioral Science. She has spent her career specializing in the implementation of genomics and precision health in healthcare systems. For over 25 years, she has conducted research on the utilization of genetic information by individuals and healthcare systems, new paradigms for identifying individuals with genomic risk, and new service delivery models for genomic testing. She has been a driver for the integration of implementation science and patient engagement to understand and study the integration of genomics into the learning health system, and is a tireless advocate of implementation science in genetic counseling. She has participated in and led many workshops and trainings on implementation science in genetics, serving as a faculty mentor for the NIH Training in Dissemination and Implementation Research in Cancer (TIDIRC) and recently as a co-lead of the Training in Dissemination and Implementation Research in Genomics and Precision Public Health (TIDIR-GPPH). She is currently a Program Director in the Division of Genomic Medicine at the National Human Genome Institute (NHGRI) where she directs the Network of Genomics-Enabled Learning Health Systems and other programs and continues to advance the integration of implementation science and genomics.   In this segment we discuss: Implementation science (IS) as a bridge between research and clinical practice in genetic counseling Misconceptions about IS, key frameworks like RE-AIM, and practical applications in daily work Using IS to identify and reduce inequities in genomic medicine Future integration of IS into training, research, and professional practice Link to the 2025 annual conference on dissemination and implementation    Segment 2: Leveraging hindsight: A retrospective chart review how-to for genetic counselors   Dr. Ramsey is the Section Chief of Individualized Therapeutics in the Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation at Children's Mercy. She is leading the implementation of a pharmacogenomics program that is fully integrated with the electronic health record, developing model-informed decision support for several medications, and Co-director of their Pediatric Clinical Pharmacology Fellowship Program. Before joining Children's Mercy, Dr. Ramsey was an Associate Professor and co-director of the Genetic Pharmacology Service at Cincinnati Children's Hospital. She completed her postdoctoral fellowship in Pharmacogenetics at St. Jude Children's Research Hospital and received her PhD in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota – Twin Cities. Dr. Ramsey is interested in all aspects of pharmacogenetics, from basic research to implementation in patient care.   In this segment we discuss: The role of retrospective chart reviews in genetic counseling research Common pitfalls such as unclear aims, time demands, and data extraction challenges Strategies for success, including SOPs, REDCap, and multidisciplinary collaboration Lessons learned on refining criteria, ensuring data quality, and team engagement   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield. 

What if prostate cancer surgery meant fewer incisions, faster recovery, and more precise cancer control? Today I'm joined by Dr. Michael D. Stifelman, Chair of Urology at Hackensack University Medical Center and a pioneer in robotic surgery with 4,000+ robotic procedures. We unpack how single-port robotics, real-time margin assessment, and AI are reshaping outcomes—while protecting continence and erections.Dr. Stifelman traces robotics from the early-2000s “pioneer phase” (and heavy skepticism) to today's standard of care, explaining why reproducibility, visualization, and tissue-sparing dexterity made the difference. We compare surgery vs. radiation (and focal therapies), when each shines, and why sequencing often matters—especially in higher-risk disease. He shares emerging tech like single-port prostatectomy, intra-operative margin evaluation (e.g., Histo-style scanning), quantitative surgical analytics, and even remote robotic assistance. We also talk “trifecta” outcomes, the role of genomics in Gleason 7 decision-making, and why lifestyle medicine and optimizing the tumor micro-environment go hand-in-hand with any treatment.Time-Stamped Highlights00:00 – Why fewer incisions + faster recovery are now real in prostate surgery05:40 – Work–life changes that improved health (sleep, exercise, biking)09:10 – Open vs. robotic: why reproducibility (teachability) matters11:05 – Robotics adoption curve: from early resistance to mainstream19:05 – Outcomes today: continence and erections after modern surgery20:10 – “Yes, I'm a surgeon—and here's my bias.” Radical honesty with patients22:05 – Offering the full menu: surveillance, focal (HIFU/cryotherapy), surgery, SBRT, proton25:40 – High-risk (Gleason 8–9): why surgery-first can preserve options & avoid long ADT34:00 – Dexterity & visualization: why robots spare nerves with less trauma35:10 – Real-time margin assessment during surgery to reduce positives40:00 – The “trifecta” (cancer control, continence, erections) and patient priorities42:10 – Genomics to risk-stratify Gleason 7 and guide surveillance vs. treatment45:00 – Future: nerve activation mapping & fluorescence to “light up” cancer46:10 – Single-port prostatectomy: smaller access, faster return of function (select patients)49:00 – Quantifying surgery with analytics; tele-mentoring & remote console potential52:30 – How to find Dr. Stifelman & closing advice

Sophie Sargent walked into the studio already owning the mic. A pandemic-era media rebel raised in New Hampshire, trained in Homeland Security (yep), and shaped by rejection, she's built a career out of DM'ing her way into rooms and then owning them. At 25, she's juggling chronic illness, chronic overachievement, and a generation that gets dismissed before it even speaks.We talk Lyme disease, Lyme denial, and the healthcare gaslighting that comes when you “look fine” but your body says otherwise. We dive into rejection as a career accelerant, mental health as content porn, and what it means to chase purpose without sacrificing identity. Sophie's a former morning radio host, country music interviewer, and Boston-based creator with a real voice—and she uses it.No fake podcast voice. No daddy-daughter moment. Just two loudmouths from different planets figuring out what it means to be seen, believed, and taken seriously in a system designed to do the opposite.Spoiler: She's smarter than I was at 25. And she'll probably be your boss someday.RELATED LINKSSophie on InstagramSophie on YouTubeSophie on LinkedInMedium article: “Redefining Rejection”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when you hand a mic to the most extroverted, uncensored Gen Z career coach in New York? You get Olivia Battinelli—adjunct professor, student advisor, mentor, speaker, and unfiltered truth-teller on everything from invisible illness to resume crimes.We talked about growing up Jewish-Italian in Westchester, surviving the Big Four's corporate Kool-Aid, and quitting a job after 7 months because the shower goals weren't working out. She runs NYU Steinhardt's internship program by day, roasts Takis and “rate my professor” trolls by night, and somehow makes room for maple syrup takes, career coaching, and a boyfriend named Dom who sounds like a supporting character from The Sopranos.She teaches kids how to talk to humans. She's allergic to BS. And she might be the most Alexis Rose-meets-Maeve Wiley-mashup ever dropped into your feed. Welcome to her first podcast interview. It's pure gold.RELATED LINKS:Olivia Battinelli on LinkedInOlivia's Liv It Up Coaching WebsiteOlivia on InstagramNYU Steinhardt Faculty PageFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On today's Unemployable, we tackle the hard stuff: why cancer remains our biggest health challenge, why water quality may define the next global conflict, how outbreaks re-enter the U.S. (measles, dengue, bioterror), what COVID actually taught us, and where AI and genomics help—or create new risks. Along the way we talk access to care, compounding vs. brand-name drugs, GLP-1s (Ozempic/Wegovy), and the habits that really move the needle: sleep, strength, hydration, and walking with purpose. My guest is a former U.S. Assistant Secretary for Health and four-star admiral in the U.S. Public Health Service with leadership roles spanning MD Anderson's Moon Shots, WHO, and federal response teams for anthrax and Ebola. It's a masterclass in population health, plain talk, and what leaders should actually do next. Timestamps below. If this helps you think clearer and lead better, hit subscribe and share it with one person who needs it today. Disclaimers: This show is educational only. Nothing here is medical advice. Talk to your doctor before making decisions about screening, vaccines, medications, or treatment. Resources mentioned: • Joxel Garcia's books on Amazon • St. Jude Children's Research Hospital • MD Anderson Moon Shots • CDC/WHO resources on vaccines & outbreaks 

This episode is sponsored by Invivyd, Inc.Marc Elia is a biotech investor, the Chairman of the Board at Invivyd, and a Long COVID patient who decided to challenge the system while still stuck inside it. He's not here for corporate platitudes, regulatory shoulder shrugs, or vaccine-era gaslighting. This is not a conversation about politics, but it's about power and choice and the right to receive care and treatment no matter your condition.In this episode, we cover everything from broken clinical pathways to meme coins and the eternal shame of being old enough to remember Eastern Airlines. Marc talks about what it means to build tools instead of just complaining, what Long COVID has done to his body and his patience, and why the illusion of “choice” in healthcare is a luxury most patients don't have.This conversation doesn't ask for empathy. It demands it.RELATED LINKSMarc Elia on LinkedInInvivyd Company SiteMarc's Bio at InvivydFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.